欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2017, Vol. 22 ›› Issue (2): 121-123.

• 专论 •    下一篇

基于物质映射的中药开发

阳国平1,3,4,裴 奇2,3,彭金富2,3   

  1. 1 中南大学湘雅三医院临床药理中心, 长沙 410013,湖南; 2 中南大学湘雅三医院药剂科, 长沙 410013,湖南; 3 湖南省药制剂优化与早期临床评价工程技术研究中心, 长沙 410013,湖南; 4 药物临床评价技术国家地方联合工程实验室, 长沙 410013,湖南
  • 收稿日期:2016-12-22 修回日期:2017-02-06 出版日期:2017-02-26 发布日期:2017-03-02
  • 作者简介:阳国平,男,教授,博士研究生导师,中南大学湘雅三医院临床药理中心主任,湖南省药制剂优化与早期临床评价工程技术研究中心常务副主任,从事临床药理学研究10多年,研究方向为新药临床评价和临床药物基因组学。 Tel:0731-88618339 E-mail:ygp9880@163.com
  • 基金资助:

    湖南省科技计划基金项目(2015TP2005)

Development of traditional Chinese medicine based on material mapping

YANG Guoping 1,3,4, PEI Qi 2,3, PENG Jinfu 2,3   

  1. 1 Center of Clinical Phamacology, 2 Pharmacy Department, the Third Xiangya Hospital of Central South University, Changsha 410013, Hunan, China; 3 Hunan Engineering Research Center for Optimization of Drug Formulation and Early Clinical Evaluation, 4 National Local Joint Engineering Laboratory for Clinical Evaluation of Drugs , Changsha 410013, Hunan, China
  • Received:2016-12-22 Revised:2017-02-06 Online:2017-02-26 Published:2017-03-02

摘要:

本文提出了中药物质映射的概念,其为真正产生药物效应的物质在不同介质中出现的利用现有的技术可获知的信息或信号和其产生的生物效应,在不同介质中的物质映射特征可用三维映射图来定性、定量描述。基于物质映射的中药开发模式不同于西药,应从临床出发,早期开展以获知临床有效性为主要目标的0期临床试验;开展从药效出发的PD/PK研究,PK研究的物质不一定为真正发挥药效的成分,而是与药效存在相关性的多种成分,可用曲面下体积(VUC)来描述药物体内暴露,PD/PK研究可用为后续的制剂优化研究提供人体评价标准;控制中药的质量标准应是涵盖从药材至成品的全程质量体系,物质映射的定性、定量描述参数是质量控制的重要组成部分;中药上市应经过严格的随机、对照临床试验确证,其人群选择和评价指标可体现中医特色,但科学的逻辑推断与西药无异。

关键词: 中药物质映射, 中药0期临床试验, PD/PK, 曲面下体积, 全程质控标准体系

Abstract:

This paper proposed the concept of material mapping of traditional Chinese medicine (TCM), which is information or signals in a variety of media and biological effects of substances with drug effects that can be detected using existing techniques. Features of material mapping in different media can be qualitatively and quantitatively described using a three-dimensional map. Based on the material mapping,TCM development model is different from western medicine, which performs early phase (0 phases) clinical trials to obtain clinical efficacy information. PD/PK researches usually study the efficacy, yet the material of PK study does not necessarily have real effects, but a variety of components related to the efficacy. The in vivo exposure of the drug can be described by the VUC (volume under the curved surface). PD/PK study provides human evaluation criteria for subsequent formulation optimization studies. Quality control of TCM should cover the whole process from materials to the finished product, and qualitative & quantitative descriptions of material mapping are important components of quality control system. Before marketing, TCM should be validated by strict randomized and controlled clinical trials. The population selection and evaluation indexes may reflect the characteristics of TCM, but there is no difference of the logic reasoning of science between western medicine and TCM.

Key words: TCM material mapping, TCM phase 0 clinical trials, PD/PK, VUC, whole quality control system

中图分类号: